Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2019

Prior Authorization for Cutaquig and Libtayo


Harvard Pilgrim requires prior authorization for the new medications Cutaquig and Libtayo for our commercial members.

Cutaquig, which was approved by the FDA in December 2018, is a subcutaneous immune globulin product used to treat primary humoral immunodeficiency in adults. Libtayo was approved in September 2018 and is used to treat patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

For both Cutaquig and Libtayo, bill the HCPCS code J3590 (unclassified biologics). To request authorization, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete criteria, please refer to our Subcutaneous Immune Globulin (SCIG) prior authorization policy and Libtayo prior authorization policy.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Improved Functionality, New Design for HPHConnect Referrals

Submitting Claims for Fidelity, Sedgwick, and Nielsen Members

Shared Decision-Making Tools for Members and Providers

CLINICIAN CORNER

NICU Program with ProgenyHealth Begins June 1

Emergency Department Overuse

Advance Care Planning Coverage (99497 & 99498)

Complex Case Management Services

Disease Management Programs Reinforce Physician Treatment Plans

Prior Authorization Required for Ilumya

Prior Authorization for Cutaquig and Libtayo

Prior Authorization Required for Onpattro

Alcohol and Drug Use Disorder: Treatment and Helpful Resources

Pharmacy and Therapeutics Committee Meeting Update

Specialty Pharmacy Program Updates

OFFICE ASSISTANT

Correct Use of Modifiers 58, 78, and 79

PUBLICATION INFORMATION

Robert Farias,
Senior Vice President, Corporate Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator